Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

Core Insights - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for treating mast cell-driven diseases and as a conditioning agent for stem cell transplants [4][5]. Company Overview - Briquilimab is being developed for chronic mast and stem cell diseases, including chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS), as well as for rare diseases like sickle cell disease (SCD), Fanconi anemia (FA), and severe combined immunodeficiency (SCID) [4][5]. - The company has demonstrated the efficacy and safety of briquilimab in over 145 participants and healthy volunteers [4][6]. Clinical Data Presentation - Jasper presented preclinical data at the European Hematology Association (EHA) Hybrid Congress, showcasing briquilimab's effects on hematopoietic stem cells (HSCs) [5][6]. - The study indicated that briquilimab inhibits SCF/c-Kit signaling without inducing apoptosis in healthy HSCs, allowing for a distinct differentiation pathway [6][8]. Mechanism of Action - Briquilimab blocks the binding of stem cell factor to c-Kit, leading to mast cell apoptosis and reducing inflammation in mast cell-driven diseases [6][8]. - The results suggest that HSCs cultured with briquilimab differentiate into CD34- cells with higher c-Kit expression, indicating a potential therapeutic pathway [7][8].